title: The study on the preparation and characterization of gene-loaded immunomagnetic albumin nanospheres and their anti-cell proliferative effect combined with magnetic fluid hyperthermia on GLC-82 cells.
abstract: As one of the most common malignant tumors, the clinical and socio-economic consequences of lung cancer are significant. Currently, surgery is the main treatment strategy for this disease, but the survival rates of lung cancer patients are not ideal due to the high recurrence rate of the disease. Therefore, many researchers are exploring new specific therapeutic methods that are highly curative and minimally cytotoxic to healthy tissues. To this end, albumin nanospheres simultaneously were loaded with super-paramagnetic iron oxide nanoparticles (as gene vector and anticancer gene), and plasmid pDONR223-IFNG, and modified with anti-EGFR monoclonal antibody cetuximab as therapy. Targeting agents, namely gene-loaded immunomagnetic albumin nanospheres (cetuximab [C225]-IFNG-IMANS), were prepared for targeted lung carcinoma cells (GLC-82 cell lines). Transmission electron microscopy images showed that the C225-IFNG-IMANS were successfully prepared, and the ability of the nanospheres to target GLC-82 cells in vitro was confirmed by Prussian blue staining, immunofluorescence experiments, and magnetic resonance imaging. Transfection photographs and agarose gel electrophoresis proved that pDONR223-IFNG could be encased in the albumin nanospheres. A Cell Counting Kit-8 assay showed that the combination therapy group had significantly more therapeutic effects on GLC-82 cells than other therapy groups. A flow cytometry assay showed that the apoptotic index of the combined treatment group was 67.68%, whereas the indices of the C225 group, gene therapy group, and magnetic fluid hyperthermia group were 12.2%, 16.34%, and 20.04% respectively. Therefore, the combination of thermal treatment, molecular targeted treatment, and gene treatment synergistically targets GLC-82 cells, and the use of C225-IFNG-IMANS as a gene or drug carrier offers a novel and promising approach for the treatment of lung cancer.
authors.affiliation: Medical School of Southeast University, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Medical School of Henan Polytechnic University, Jiaozuo, Henan, People's Republic of China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Hou
authors.affiliation: Taizhou People's Hospital Affiliated to Nantong University, Taizhou, Jiangsu, People's Republic of China.
authors.forename: Mei
authors.initials: M
authors.lastname: Lin
authors.affiliation: Medical School of Southeast University, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Ultrasound in Medicine, The First Affiliated Hospital (Jiangsu Province Hospital of TCM), Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Hongbo
authors.initials: H
authors.lastname: Li
authors.affiliation: Medical School of Southeast University, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Chenyan
authors.initials: C
authors.lastname: Yuan
authors.affiliation: Medical School of Southeast University, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Chen
authors.initials: C
authors.lastname: Liang
authors.affiliation: Jiangsu Cancer Hospital, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Medical School of Southeast University, Nanjing, Jiangsu, People's Republic of China ; Jiangsu Key Laboratory For Biomaterials and Devices, Nanjing, Jiangsu, People's Republic of China.
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Zhang
mesh_terms: D000418:Albumins / Q000737:chemistry* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D000068818:Cetuximab / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004337:Drug Carriers; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007036:Hypothermia, Induced; D007097:Imines / Q000737:chemistry; D007371:Interferon-gamma / Q000235:genetics / Q000378:metabolism; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles / Q000737:chemistry*; D046529:Microscopy, Electron, Transmission; D011095:Polyethylenes / Q000737:chemistry; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D013997:Time Factors; D014162:Transfection
chemical_list: D000418:Albumins; D000970:Antineoplastic Agents; D004337:Drug Carriers; D007097:Imines; D058185:Magnetite Nanoparticles; D011095:Polyethylenes; D047428:Protein Kinase Inhibitors; C505405:poly(ethylene imine); D007371:Interferon-gamma; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: magnetic nanoparticles; nano-drug; targeting gene therapy